First, immunoblot analysis demonstrated gilteritinib inhibits ALK autophosphorylation in both EML4-ALK-carrying Ba/F3 cells and ALK-positive NSCLC cells. This evidence concerns the gene EML4 and non-small cell lung carcinoma.